A PHP Error was encountered

Severity: Warning

Message: Creating default object from empty value

Filename: models/publicacao_item.php

Line Number: 20

Meta-analysis: the safety and efficacy of vaptans (tolvaptan,... » Isaúde
  Pesquisar Publicações Científicas  
  Especialidade: carregando especialidades...  Carregando...
Nome da revista:   Volume:   Número:
Alimentary Pharmacology and Therapeutics
2012-08-22 03:00:47

Meta-analysis: the safety and efficacy of vaptans (tolvaptan, satavaptan and lixivaptan) in cirrhosis with ascites or hyponatraemia

Descrição: BackgroundVaptans may correct hyponatraemia and mobilise ascites through an increased excretion of water. The effect on clinical outcomes is debated.AimTo determine the effects of vaptans (tolvaptan, satavaptan and lixivaptan) on patients with cirrhosis and hyponatraemia or ascites.MethodsSystematic review of randomised controlled trials. The primary outcome measure was mortality. Electronic and manual searches were combined (April 2012). Data were extracted from published reports, online information from the Food and Drug Administration website or obtained through correspondence with authors and pharmaceutical companies. The primary meta-analyses were performed using random effects models due to an expected clinical diversity.ResultsTwelve trials with a total of 2266 patients were included. Randomisation was adequate in all trials. Eight trials were double-blind. Random effects meta-analyses found no clear differences between vaptans and control groups regarding mortality (RR?=?1.06, 95% CI?=?0.90-1.26, I2?=?0%), variceal bleeding, hepatic encephalopathy, spontaneous bacterial peritonitis, hepatorenal syndrome, or renal failure. Vaptans increased serum sodium levels (WMD?=?1.8?mmol/L, 95% CI?=?0.79-2.96) and lead to reductions in weight and the time to the first paracenthesis. Vaptans increased the risk of adverse events (RR?=?3.97, 95% CI?=?1.78-8.83), including an excessive urine volume (RR?=?9.96, 95% CI?=?1.38-71.68).ConclusionsVaptans have a small beneficial effect on hyponatraemia and ascites, but do not affect mortality, complications to cirrhosis or renal failure. The data do not support the routine use of vaptans in cirrhosis.

Editorial: John Wiley & Sons, Inc.
Seção: Meta-analysis
Volume: 0
Página: 619 a 626


Mais informações

  • Twitter iSaúde
publicidade
Jornal Informe Saúde

Indique o portal
Fechar [X]
  • Você está indicando a notícia: http://www.isaude.net
  • Para que seu amigo(a) receba esta indicação preencha os dados abaixo:

RSS notícias do portal  iSaúde.net
Receba o newsletter do portal  iSaúde.net
Indique o portal iSaúde.net
Notícias do  iSaúde.net em seu blog ou site.
Receba notícias com assunto de seu interesse.
© 2000-2011 www.isaude.net Todos os direitos reservados.